1. Home
  2. KZIA vs FBGL Comparison

KZIA vs FBGL Comparison

Compare KZIA & FBGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KZIA
  • FBGL
  • Stock Information
  • Founded
  • KZIA 1994
  • FBGL 1996
  • Country
  • KZIA Australia
  • FBGL Singapore
  • Employees
  • KZIA N/A
  • FBGL N/A
  • Industry
  • KZIA Biotechnology: Pharmaceutical Preparations
  • FBGL Miscellaneous manufacturing industries
  • Sector
  • KZIA Health Care
  • FBGL Consumer Discretionary
  • Exchange
  • KZIA Nasdaq
  • FBGL Nasdaq
  • Market Cap
  • KZIA 9.0M
  • FBGL 9.0M
  • IPO Year
  • KZIA 1999
  • FBGL 2025
  • Fundamental
  • Price
  • KZIA $7.94
  • FBGL $0.70
  • Analyst Decision
  • KZIA Strong Buy
  • FBGL
  • Analyst Count
  • KZIA 2
  • FBGL 0
  • Target Price
  • KZIA $14.00
  • FBGL N/A
  • AVG Volume (30 Days)
  • KZIA 137.3K
  • FBGL 683.5K
  • Earning Date
  • KZIA 11-14-2025
  • FBGL 01-01-0001
  • Dividend Yield
  • KZIA N/A
  • FBGL N/A
  • EPS Growth
  • KZIA N/A
  • FBGL N/A
  • EPS
  • KZIA N/A
  • FBGL N/A
  • Revenue
  • KZIA $1,549,158.00
  • FBGL $10,146,582.00
  • Revenue This Year
  • KZIA N/A
  • FBGL N/A
  • Revenue Next Year
  • KZIA $49.25
  • FBGL N/A
  • P/E Ratio
  • KZIA N/A
  • FBGL N/A
  • Revenue Growth
  • KZIA 248983.08
  • FBGL N/A
  • 52 Week Low
  • KZIA $2.86
  • FBGL $0.44
  • 52 Week High
  • KZIA $39.05
  • FBGL $5.45
  • Technical
  • Relative Strength Index (RSI)
  • KZIA 48.43
  • FBGL N/A
  • Support Level
  • KZIA $7.60
  • FBGL N/A
  • Resistance Level
  • KZIA $8.28
  • FBGL N/A
  • Average True Range (ATR)
  • KZIA 0.51
  • FBGL 0.00
  • MACD
  • KZIA 0.03
  • FBGL 0.00
  • Stochastic Oscillator
  • KZIA 30.88
  • FBGL 0.00

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.

Share on Social Networks: